Program Directors: Eileen Dolan, Peter O'Donnell and Mark Ratain
Administrator: Lexi Nash Smith
Phone: 4-8429
Openings: 0 Predoctoral, 6 Postdoctoral
This training program has been designed to provide an education in a broad range of academic clinical pharmacology activities through exposure to both research and clinical activities and studies. The Committee on Clinical Pharmacology and Pharmacogenomics is comprised of faculty in the Departments of Anesthesia and Critical Care, Human Genetics, Medicine, Psychiatry, and Pediatrics. Each trainee follows an individually designed program based on his or her background, with minimal core requirements. It is anticipated that most fellows will have a M.D. degree, will have completed their residency training and will be eligible for board certification in their selected specialty. However, qualified applicants with a Ph.D. and Pharm.D. in a relevant discipline will be considered for acceptance into the program. It is also anticipated that some applicants with a M.D. degree will have completed a period of fellowship training in a selected sub-specialty. Applicants are expected to complete a 2-3 year period of training, at the end of which they should be qualified to address clinical pharmacologic issues and research questions within their specialty, as well as be prepared for board certification.
*One slot allocated for a Pediatric Clinical Pharmacology Trainee
Additional Information: More information on fellowship training in clinical pharmacology and pharmacogenomics is available at the program website.
Training Faculty
- Dolan, M. Eileen: Pharmacogenetics of anticancer agents
- O’Donnell, Peter: Pharmacogenetics/Pharmacogenomics
- Ratain, Mark J.: Pharmacogenetics/Pharmacogenomics
- Apfelbaum, Jeffrey: New standards of care and practice parameters, pharmacogeno mics in perioperative care
- Applebaum, Mark: Epigenetics, neuroblastoma, target identification
- Bakris, George: Understanding ethnic disparities in kidney disease development and progression
- Chapman, Arlene: Polycystic kidney disease and hypertension
- Cohn, Susan: Pediatric cancers and blood diseases
- Cunningham, Patrick: Pharmacogenomics of HTN
- Das, Soma: Molecular diagnosis of human genetic disease
- Desai, Ami: Clinical Drug Development; biomarkers of therapy response and resistance
- de Wit, Harriet: Pharmacogenomics of substance abuse
- Di Rienzo, Anna: Population genetics
- Fleming, Gini: Novel therapeutics in breast, ovarian, and endometrial cancers
- Gajewski, Thomas: Developing new treatments in melanoma
- Kline, Justin: Developing immunotherapies for patients with hematologic malignancies
- Kron, Stephen: Cell stress response
- Kupfer, Sonia: Colorectal cancer, inflammatory bowel disease
- LaBelle, James: Cancer and Immune Chemical Biology
- Nagele, Peter: Perioperative pharmacogenetics, cardiac events
- Olopade, Olufunmilayo: Improve cancer outcomes and reduce health disparities
- Park, Deric: Developmental therapeutics Cell biology/signaling
- Patnaik, Akash: Therapeutic strategies to enhance immune- responsiveness in prostate cancer
- Pisano, Jennifer: Antimicrobial stewardship
- Reid, Pankti: Rheumatology
- Siegler, Mark: Clinical medical ethics
- Stock, Wendy: Acute Leukemia
- Strek, Mary: Pharmacotherapy for asthma
- Sweis, Randy: Cancer immunotherapy, developmental therapeutics
- Szmulewitz, Russell: Evolution and management of metastatic and castration resistant prostate cancer
- Weichselbaum, Ralph: Treatment of oligo metastasis with radiotherapy
- Yeo, Kiang-Teck Jerry: Cardiac Biomarkers, Clinical Pharmacogeno mics and Mass Spectrometry
- Yuan, Chun-Su: Opioid pharmacology and botanical studies